-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Canocapavir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/2137847-19-7.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2137847-19-7 |
| Description | Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. |
Product Information
| Synonyms | Canocapavir|Canocapavir [INN]|UNII-ITF8H4SZR1|ITF8H4SZR1|SCHEMBL20718857|HY-147255|CS-0542309|2137847-19-7|2H-Benzimidazol-2-one, 5-(2-((2R)-2-(1-(4-bromophenyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl)-4-oxo-3-oxazolidinyl)ethyl)-1,3-dihydro-|5-(2-((2R)-2-(1-(4-Bromophenyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl)-4-oxo-3-oxazolidinyl)ethyl)-1,3-dihydro-2H-benzimidazol-2-one|5-(2-((2R)-2-(1-(4-Bromophenyl)-3-(4-fluorophenyl)-1hpyrazol- 4-yl)-4-oxo-1,3-oxazolidin-3-yl)ethyl)-1,3- dihydro-2H-benzimidazol-2-one |
| Molecular Weight | 562.39 |
| Molecular Formula | C27H21BrFN5O3 |
| Canonical SMILES | C1C(=O)N(C(O1)C2=CN(N=C2C3=CC=C(C=C3)F)C4=CC=C(C=C4)Br)CCC5=CC6=C(C=C5)NC(=O)N6 |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 837 |
| Exact Mass | 561.08118 |
| Target | HBV |
| XLogP3-AA | 4 |